ResMed Stock - Morgan Stanley downgrade keeps pressure on sleep-apnea specialist

ResMed stock remains under scrutiny after a recent downgrade from Morgan Stanley tied to GLP-1 weight-loss drugs and renewed competition from Philips. A look at the week’s developments, sector context and what still drives the business.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 14:04 CET. Details in the imprint.

ResMed (US7611521078) stays in the analyst spotlight after a recent downgrade that has sharpened the debate around its growth outlook. Morgan Stanley cut its rating citing GLP-1 weight-loss drugs and returning competition from Philips, according to a summary of the bank’s note.

Morgan Stanley turns more cautious

Morgan Stanley recently lowered its stance on ResMed from Overweight to Equal Weight, pointing to limited scope for a valuation re-rating in the near term.

The bank’s analysts flag competitive pressures from GLP-1 weight-loss therapies, which could reduce the incidence or severity of obstructive sleep apnea, and the potential full return of Philips into the U.S. sleep-device market.

Weekly review and sector backdrop

The downgrade comes against a backdrop of already soft share performance, with ResMed shares showing a negative return over the past year as investors reassess growth and margin prospects.

Simply Wall St calculates a fair value for the stock well above the current market price, arguing ResMed could be more than 30% undervalued despite recent pressure.

The product behind the stock

ResMed generates most of its revenue from devices and cloud-connected systems to diagnose and treat sleep-disordered breathing, including its AirSense range of continuous positive airway pressure (CPAP) machines and related masks.

Where the stock trades today

ResMed shares (US7611521078) trade on the New York Stock Exchange at $188.63 as of 06/19/2026, 14:04 CET.

Key facts on ResMed stock

• Company: ResMed Inc.
• ISIN: US7611521078
• WKN: 895279
• Ticker: RMD
• Venue: NYSE
• Price (as of 06/19/2026, 14:04 CET): 188.63 USD
• Market cap: 27,400,000,000 USD (as of 06/19/2026)
• Sector / Industry: Health Care - Medical Equipment
• Index membership: S&P 500
• Next earnings date: 08/08/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.